• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ICON’s Full-Year Revenues up 37%

ICON’s Full-Year Revenues up 37%

February 24, 2009
CenterWatch Staff

ICON posted another quarter of growth and closed out 2008 with revenue growth of 37% to $865 million.  Fourth quarter revenues increased 22% over Q4 2007 to $220 million.

Net income for the year was $78.1 million or $1.30 per share, compared with $56 million or $0.94 per share, last year, and net revenue for the fourth quarter was $21 million or 35 cents per share on a diluted basis, compared with $15.9 million or 26 cents per share last year.

The Dublin, Ireland-based contract research organization (CRO) completed 2008 on the high-end of its revenue guidance, which was reforecast in January to be in the range of $862 million to $865 million.

“We are very satisfied with our performance in quarter four,” said ICON CEO Peter Gray in a company statement. “With our backlog at $1.74 billion we have entered 2009 in a good position, although the difficult economic climate has put some customers under pressure and has created a degree of uncertainty. We remain positive, though cautious, as 2009 commences.”

ICON acquired Healthcare Discoveries in February 2008 and Prevalere Life Sciences in November 2008. Both companies “modestly” exceeded their original acquisition criteria, said chief financial officer Ciaran Murray in an investor call Monday. The company also added nearly 1,400 staff in 2008, bringing its total employee base to 7,000.

Upcoming Events

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing